The size of palatine tonsils cannot be used to decide the indication of tonsillectomy for IgA nephropathy

Mitsuhiro Sato1, Mika Adachi2, Hideyuki Kosukegawa1, Yuri Nomura2, Kenichi Watanabe2, Toshinobu Sato1 and Yoshio Taguma1

1Department of Nephrology, Japan Community Healthcare Organization Sendai Hospital, Sendai, Miyagi, Japan and 2Department of Otorhinolaryngology, Head and Neck Surgery, Tohoku University School of Medicine, Sendai, Miyagi, Japan

Correspondence to: Mitsuhiro Sato; E-mail: dresea@aol.com

Discussion

The size of palatine tonsils cannot be used to decide the indication of tonsillectomy for IgA nephropathy. The relationship between the indication of tonsillectomy and the size of palatine tonsils (PTs) in patients with IgAN remains controversial.

Methods.
This retrospective cohort study investigated 57 patients with IgAN who underwent tonsillectomy combined with steroid pulse therapy (SPT). They were classified into two groups, the hypertrophy group and the nonhypertrophy group, according to the weight of their excised PTs. The effects of tonsillectomy combined with SPT on clinical remission (CR) and the histopathological findings of PTs were compared between the two groups.

Results.
During the mean follow-up period of 45.5 (range 6–133) months, 78.9% of the patients achieved CR (79.3 versus 78.6%, P = 0.945) and the baseline serum creatinine doubled only in one patient in the nonhypertrophy group (0 versus 3.6%, P = 0.491). No significant difference was observed in the incidence of CR between the two groups by the Kaplan–Meier method (P = 0.839). The predictor for CR, identified in Cox proportional hazards models, was baseline proteinuria [hazard ratio 0.14 (95% CI 0.032–0.621) P = 0.010]. Although macroscopic pus plugs were observed on the surface of PTs in almost 60% of patients in each group, microscopic pus plugs in the crypt and the enlarged interfollicular area were observed in all patients.

Conclusions.
The treatment effect of tonsillectomy combined with SPT and the pathological features of PTs in IgAN were equal, regardless of the size of the PTs. Therefore, the size of PTs should not be included as a factor when deciding the indication of tonsillectomy for IgAN.

Key words: chronic inflammation; hematuria; IgA nephropathy; proteinuria; tonsillectomy

Introduction

Immunoglobulin A nephropathy (IgAN), the most common form of glomerulonephritis worldwide, is characterized by a highly variable clinical course [1]. However, many patients progress slowly and 30–40% of patients develop end-stage renal failure (ESRF) over a 20-year period from its onset [2]. Although a disease-specific treatment modality of IgAN has not yet been established, tonsillectomy has been considered as...
one of the treatment strategies in Asia, especially in Japan, based on the theory of focal infection [3]. However, tonsillectomy has not been considered outside Asia because of insufficient evidence.

Clinical studies of tonsillectomy for IgAN have been reported since the 1980s, but their observation periods were <10 years and their conclusions varied due to the levels of renal dysfunction and histopathological damage [4–6]. However, in the early 2000s, a retrospective cohort study with a long follow-up of 16 ± 6 years resulted in the first report of a lower incidence of ESRF in a tonsillectomy group compared with a non-tonsillectomy group [7]. Additionally, in a nonrandomized comparative study, Komatsu et al. [8] reported that the normalization rate of urinary findings was higher with tonsillectomy combined with steroid pulse therapy (SPT) compared with SPT alone. A recent randomized control trial (RCT) reported that tonsillectomy combined with SPT was more effective than SPT alone in reducing urinary protein (UP) after 1 year [9].

Despite many reports having been published about tonsillectomy for IgAN, to our knowledge, no studies to date have focused on the size of palatine tonsils (PTs). The relationship between the indication of tonsillectomy and the size of PTs in patients with IgAN has not yet been established. Because of the lack of information concerning the size of PTs in IgAN, most nephrologists tend to consider the small, nonhypertrophic tonsils as nonindicative of tonsillectomy. Therefore, we conducted a retrospective cohort study to evaluate the impact of the size of PTs on the effect of tonsillectomy combined with SPT and the histopathological findings of tonsils.

Materials and methods

Patients

We identified 347 patients with histologically proven IgAN by renal biopsy between September 2003 and November 2005. The histological diagnosis was based on light microscopy and immunohistochemistry findings. Tonsillectomies were performed for the treatment of IgAN in 307 patients by two surgeons using the same operative method between January 2004 and December 2005. We included patients who had undergone SPT within half a year of the operation and who had no immunosuppressive treatment before the surgery. Patients with systemic lupus erythematosus, chronic liver disease, diabetic nephropathy and who were <15 years old were excluded. The final analysis was performed on a group of 57 IgAN patients. According to the median weight of their excised PTs, 57 patients were categorized into two groups: (1) the hypertrophic group, PT weight ≥3.0 g (n = 29) and (2) the nonhypertrophic group, PT weight <3.0 g (n = 28).

The study protocol was approved by the ethical committees in our institution.

Treatment regimens

Tonsillectomies were performed according to the essential elements of the indication criteria by Akagi et al. [10]: (1) definitive diagnosis of IgAN by renal biopsy and (2) renal pathology grade [11] <II and serum creatinine ≤2 mg/dL. SPT was usually used when active lesions were present in the biopsy specimen. However, this activity is not always represented in the restricted area of a biopsy specimen. Thus, after obtaining informed consent from each patient, for those without apparent active lesions, SPT was also administered for the treatment target of clinical remission (CR) regarding urinary findings [8], regardless of the degree of proteinuria. The regimen of SPT was intravenous methylprednisolone 0.5 g/day for 3 days for two or three courses, usually followed by oral prednisolone at an initial dose of 0.6 mg/kg on alternate days, with a decrease of 0.1 mg/kg every 2 months. Because of the retrospective nature of this study, the supportive therapy protocol, which included oral medication of renin–angiotensin system (RAS) inhibitor and antplatelet agents (dipyridamole, dilazep dihydrochloride), was not predetermined and depended exclusively on individual nephrologists.

Measurements

Baseline characteristics preceding tonsillectomy were collected retrospectively from patients’ medical records and included age, sex, body mass index, serum concentration of creatinine, estimated glomerular filtration rate (eGFR), UP excretion, hematuria, serum IgA, systolic and diastolic blood pressure (BP), history of macroscopic hematuria and smoking status. Serum IgA after tonsillectomy was also collected to compare it with the baseline. The hematuria was scored as urinary erythrocytes of 0/high-power field (HPF) (1), 1–4/HPF (2), 5–9/HPF (3), 10–29/HPF (4), 30–49/HPF (5) or ≥50/HPF (6). To determine histological severity, two nephrologists with extensive experience in the diagnosis of IgAN conducted assessments according to the Oxford classification [12, 13]: mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S) and tubular atrophy/interstitial fibrosis (T). In addition, the total numbers of glomeruli and global sclerosis, tuft necrosis, cellular crescent, fibrocellular crescent and fibrous crescent were evaluated. We also collected the histopathological findings of PTs (macroscopic and microscopic pus plugs) in addition to the weight of the excised PTs and the scores of the Mackenzie scale. Microscopic pus plugs were evaluated by hematoxylin and eosin–stained sections via light microscopy. Adverse effects of corticosteroid and tonsillectomy, including hospitalization caused by infection, steroid-induced hyperglycemia, gastrointestinal bleeding, mental disorder, surgical therapy for aseptic osteonecrosis, postoperative bleeding and postoperative dysgeusia, were also collected from the medical records.

Outcome

The primary outcome was CR of urinary abnormalities defined as both hematuria and proteinuria remission: three consecutive negative results over a 6-month period in urinary sediment red blood cell count of <5/HPF (hematuria remission) and a proteinuria qualitative reaction of (−) to (±) (proteinuria remission) referring to the remission criteria [14]. We also analyzed a secondary outcome: a 50% increase of serum creatinine from baseline.

Statistical analyses

Variables showing a normal distribution were described as means and standard deviations and compared using the Student’s t-test. Variables without a normal distribution were described as medians and interquartile ranges and compared using the Mann–Whitney U test or Wilcoxon signed-rank test. We used the chi-squared test (or Fisher’s test) for data expressed as proportions.

The cumulative probability of CR was calculated using Kaplan–Meier methods. The effectiveness of the weight of excised PTs on this outcome was compared using the log-rank test and univariate and multivariate Cox proportional hazards
The assumption of constant hazard rates over time was checked by plotting the logarithm of the survivor function against time. The statistical significance level was set at $P < 0.05$. All statistical analyses were performed with the statistical package SPSS for Windows (version 19.0; SPSS, Chicago, IL, USA).

### Results

#### Baseline characteristics

The baseline characteristics of the hypertrophic ($n = 29$) and nonhypertrophic ($n = 28$) groups are described in Table 1. The hypertrophic group had a significantly higher proportion of males (65.5 versus 35.7%; $P = 0.024$) and higher eGFR (mean ± SD = 92.8 ± 21.2 versus 81.5 ± 19.9 mL/min/1.73 m$^2$; $P = 0.021$) compared with those characteristics for the nonhypertrophic group. No statistical difference was observed between the two groups in the use of RAS inhibitor and antiplatelet agents (Table 4). When these four predictors were included in the multivariate Cox proportional hazards model together with the clinically and histologically important predictors (weight of excised PTs, eGFR, diastolic BP, global sclerosis), proteinuria was the only significant predictor [Table 5; HR 0.14 (95% CI 0.032–0.621); $P = 0.010$].

#### Outcome events

The mean observation period of the whole cohort ($n = 57$) was 45.5 months, ranging from 6 to 133 months. The frequencies of hematuria remission and proteinuria remission are indicated in Table 3. The value of serum IgA after tonsillectomy was measured in 22 patients (75.9%) in the hypertrophic group and 14 patients (50.0%) in the nonhypertrophic group. The values decreased significantly in both groups (Table 6).

#### Tonsillar histological findings

Macroscopic pus plugs on the surfaces of PTs were observed in 17 patients (58.6%) in the hypertrophic group and 17 patients (60.7%) in the nonhypertrophic group. However, microscopic pus plugs in the crypt were observed in all patients in both groups. Moreover, an enlarged interfollicular area, considered to be a pathological finding that is specific to PTs of IgAN [15, 16], was also observed in all specimens (Figure 2).

#### Changes of serum IgA after tonsillectomy

The value of serum IgA after tonsillectomy was measured in 22 patients (75.9%) in the hypertrophic group and 14 patients (50.0%) in the nonhypertrophic group. The values decreased significantly in both groups (Table 6).
Adverse effect of SPT and tonsillectomy

No significant difference was observed between the hypertrophic group and the nonhypertrophic group in hospitalization caused by infection \( n = 0 \) versus \( n = 1 \) (3.6%); \( P = 0.491 \), steroid-induced hyperglycemia \( n = 2 \) (6.9%) versus \( n = 1 \) (3.6%); \( P = 0.513 \) and postoperative dysgeusia \( n = 2 \) (6.9%) versus \( n = 0 \) (0%); \( P = 0.254 \). These adverse effects completely disappeared with adequate therapeutic measures. No patients in either group were diagnosed with gastroduodenal bleeding, mental disorder or postoperative bleeding, nor were surgical therapies required for any patients.

Discussion

To our knowledge, this is the first report to address the quantitative analysis of the size of PTs in IgAN. The major findings of this study are that even small, nonhypertrophic tonsils have similar pathological features to hypertrophic tonsils in IgAN and that the treatment effect of tonsillectomy combined with SPT is equal regardless of the size of PTs. Therefore, the size of PTs is not an issue when deciding the indication of tonsillectomy for IgAN.

Macroscopic pus plugs in the tonsillar lacunae are often observed in patients with IgAN [17]. Practically, macroscopic pus plugs in the tonsillar lacunae can also be observed in patients who had no sign of them 2 or 3 days before. This means that the presence of macroscopic pus plugs is variable in a relatively short time. Thus the presence of pus plugs on the surface of PTs does not affect the treatment [17]. Even in patients without macroscopic pus plugs, microscopic pus plugs were observed in this study.

Histologically, the tissues of tonsils consist of three microcompartments: the crypt epithelium, interfollicular area and lymphoid follicle [18]. The interfollicular area is an important place where the antigen-specific T cell activation and subsequent T cell–B cell interaction takes place [19]. Kawaguchi et al. [15] and Takechi et al. [16] previously reported that enlarged interfollicular areas of tonsils were characteristic of IgAN. In this study, interfollicular areas were characteristically expanded both in the hypertrophic group and in the nonhypertrophic group. This means that even non-hypertrophic PTs may have immunoreactive power. With regard to response to treatment, no particular differences were observed in the histopathological findings of PTs between patients with and without CR in this study. We were unable to find any other reports concerning this comparison. The PTs of IgAN have specific pathological findings. However, it is still difficult to predict the prognosis after treatment intervention based on the pathological findings of PTs. This point may be a target of future study.

The efficacy of tonsillectomy for reducing the incidence of ESRF was reported by a long follow-up cohort study [7]. However, use of the size of tonsils as a factor of indication for tonsillectomy in IgAN has been controversial. Otolaryngologically, the main indication for tonsillectomy is
upper airway obstruction due to tonsillar hypertrophy as well as recurrent acute or chronic tonsillitis. Therefore, most nephrologists tend to consider small, non-hypertrophic tonsils as nonindicative for tonsillectomy in IgAN.

Matsutani et al. [17] indicated that it was difficult to predict the efficacy of tonsillectomy based on the size of PTs. On the other hand, Tabata et al. [20] reported that urinary remission by tonsillectomy was achieved in patients with a higher degree of tonsillar hypertrophy. This inconsistent argument may be due to the subjective method used to evaluate tonsil size. Previous studies macroscopically evaluated the size of tonsils using the Mackenzie scale, which is not an absolute measurement. This scale might be influenced by structural variations in the components of the lateral pharyngeal wall. Therefore, we quantitatively evaluated the size of tonsils by measuring their weight.

For evaluation of CR, we used the proposed criteria based on a nationwide opinion survey in Japan [14]. Among the items in the criteria, we used urinary sediment red blood cell count as hematuria remission and proteinuria qualitative reaction as proteinuria remission in this study. The evaluations for hematuria and proteinuria were semiquantitative and qualitative, respectively. We did not use the urine occult blood reaction by test paper and proteinuria amount (g/g creatinine), because the former may induce false positives and negatives [14] and the latter was not evaluated for every outpatient visit among our patients.

Moderate or heavy proteinuria is considered to be a prognostic factor in IgAN. It may be reasonable to assume that the patients included in this study would have a good prognosis even without any specific intervention. However, from the viewpoint of chronic kidney disease, even microalbuminuria is a risk factor of cardiovascular disease [21]. In addition, several studies have demonstrated that 7–20% of IgAN patients with hematuria alone or hematuria coexistent with mild proteinuria show a decrease in renal function over long-term observation [22, 23]. These reports indicate that not only is a larger amount of proteinuria important as a prognostic factor, but that hematuria...

![Fig. 1. Cumulative probability of clinical remission by the Kaplan–Meier analysis in the hypertrophic (n = 29, solid line) and nonhypertrophic (n = 28, dashed line) groups. See the text for the definition of each group. Probability was analyzed according to the log-rank test (P = 0.839).](image1)

Table 4. Univariate analysis of predictors of clinical remission

| Predictors                      | HR   | 95% CI          | P-value |
|---------------------------------|------|----------------|---------|
| Weight of excised PTs           | 0.929| 0.701–1.231     | 0.608   |
| Age                             | 0.982| 0.961–1.003     | 0.098   |
| Male (versus female)            | 1.027| 0.568–1.857     | 0.930   |
| Body mass index                 | 0.950| 0.869–1.038     | 0.254   |
| Serum creatinine                | 0.353| 0.081–1.542     | 0.166   |
| eGFR                            | 1.012| 0.998–1.027     | 0.088   |
| Proteinuria                     | 0.120| 0.030–0.478     | 0.003   |
| Hematuria                       | 1.008| 0.799–1.272     | 0.947   |
| Serum IgA                       | 1.000| 0.997–1.002     | 0.908   |
| SBP, mmHg                       | 0.979| 0.961–0.998     | 0.030   |
| DBP, mmHg                       | 0.971| 0.943–1.000     | 0.050   |
| Use of RAS inhibitor            | 0.339| 0.165–0.696     | 0.003   |
| Use of antplatelet agents       | 0.462| 0.248–0.861     | 0.015   |
| Mesangial hypercellularity      | 0.824| 0.367–1.850     | 0.638   |
| Segmental sclerosis             | 1.239| 0.674–2.278     | 0.490   |
| Endocapillary hypercellularity  | 1.363| 0.684–2.716     | 0.378   |
| Tubular atrophy/interstitial fibrosis | 0.583 | 0.283–1.202 | 0.144 |
| Global sclerosis                | 0.952| 0.858–1.055     | 0.349   |
| Tuft necrosis                   | 0.639| 0.267–1.527     | 0.313   |
| Cellular crescent               | 0.989| 0.723–1.353     | 0.944   |
| Fibrocellular crescent          | 0.912| 0.776–1.071     | 0.261   |
| Fibrous crescent                | 1.130| 0.890–1.436     | 0.315   |

SBP, systolic blood pressure; DBP, diastolic blood pressure.

Table 5. Multivariate analysis of predictors of clinical remission

| Predictors                      | HR   | 95% CI          | P-value |
|---------------------------------|------|----------------|---------|
| Weight of excised PTs           | 0.833| 0.617–1.123     | 0.230   |
| eGFR                            | 1.008| 0.987–1.030     | 0.456   |
| Proteinuria                     | 0.140| 0.032–0.621     | 0.010   |
| SBP                             | 0.996| 0.961–1.032     | 0.838   |
| DBP                             | 0.987| 0.929–1.049     | 0.679   |
| Use of RAS                       | 0.552| 0.189–1.611     | 0.277   |
| Use of antplatelet agents       | 0.648| 0.326–1.292     | 0.218   |
| Global sclerosis                | 1.011| 0.874–1.170     | 0.885   |

SBP, systolic blood pressure; DBP, diastolic blood pressure.
and/or mild proteinuria are as well. Moreover, achieving CR lightens the patient’s burden of regularly attending hospital and taking medicine, which may continue for life. Accordingly, we set a treatment target of ‘remission of nephropathy’ rather than ‘slowing the progression of nephropathy’. We evaluated neither hematuria nor proteinuria alone, but rather both together as a stronger endpoint of CR.

An RCT has shown that SPT is more effective than conventional steroid therapy for long-term preservation of renal function [24]. However, the remission ratio of proteinuria was not significantly high and severe proteinuria reappeared among some of the patients after the cessation of treatment. Additionally, hematuria, which is considered to be a prognostic factor in the early stage of the disease [25], was not evaluated. On the other hand, in a nonrandomized comparative study, Komatsu et al. [8] reported that the normalization rate of urinary findings including hematuria was higher with tonsillec-toomy combined with SPT compared to SPT alone. Furthermore, a recent RCT reported that tonsillec-toomy combined with SPT was more effective than SPT alone in reducing UP [9]. IgAN has been considered to be one of the focal infections, like palmoplantar pustulosis. Consequently, the removal of infection would constitute a treatment strategy [3].

Previous studies on the efficacy of tonsillec-toomy for IgAN have yielded different results owing to the levels of renal dysfunction, histopathological damage and other criteria [4–6]. The follow-up period is also considered to be a such factor. Research that showed negative results in the efficacy of tonsillec-toomy had a follow-up period of <10 years [6, 26]. Conversely, those that showed positive results had a longer follow-up period. For example, the follow-up period of the report by Agaki et al. [27] was 13 years while that of Xie et al. [7] was 16 years. Although the report by Chen et al. [28], with a follow-up period of 11 years, showed a negative result, they mentioned in their discussion section that ‘perhaps a longer follow-up might reveal a statistical significant difference’. Recently, Feehally et al. [29] reported that no significant correlation was found between tonsillec-toomy and a decline in renal function over a follow-up of 4.7 years in the VALIGA cohort. On the basis of the previous reports, a longer follow-up may be needed for a more proper evaluation. In the Kidney Disease: Improving Global Outcomes clinical practice guidelines for glomerulonephritis, tonsillec-toomy is not recommended because no RCT has been performed for IgAN [30]. However, it is difficult to get high-level evidence concerning the efficacy of tonsillec-toomy with an RCT study because it takes nearly 15 years to evaluate the efficacy of tonsillec-toomy on the outcome of ESRF [7].

The two main pathways for the pathogenetic mechanisms of IgAN, upstream and downstream, have been proposed as an action mechanism of this combination therapy [31]. The ‘upstream’ pathway is continuous antigenic stimulation of the innate immune system by the tonsillar mucosa via the mucosa–bone marrow axis. In the ‘downstream’ pathway, the anomalously stimulated immune response in bone marrow results in the production of aberrantly glycosylated IgA1 and its subsequent deposition within the mesangium. Such deposition leads to inflammation in renal glomeruli. From this viewpoint, a tonsillec-toomy may affect the upstream pathway of the pathogenic mechanism by eliminating antigenic stimuli from the tonsillar mucosa. SPT may influence the downstream pathway of the immunological mechanism by suppressing the abnormal immune response in the bone marrow, inducing inflammation in glomeruli. Therefore, tonsillec-toomy combined with SPT can have an improved therapeutic effect on IgAN compared with SPT alone, tonsillec-toomy alone, or neither.

The CR rate of urinary findings by tonsillec-toomy combined with SPT was 79% after a period of ~45 months. A previous analysis reported that ~60% of patients with moderate or heavy proteinuria who underwent this combination therapy achieved CR [8]. These results indicate that a higher CR rate may be expected in patients with milder proteinuria. It is possible that our results are influenced not only by tonsillec-toomy combined with SPT but also by combining other drugs such as RAS inhibitor and antipla-telet agents. However, the supportive therapy was not administered to all patients. Thus the main therapeutic factor for this result is tonsillec-toomy combined with SPT, which all patients underwent.

The age of the hypertrophic group was younger than that of the nonhypertrophic group, but the difference was not statistically significant. The relationship between tonsillar size and age has never been elucidated in IgAN. Interestingly, Cahali et al. [32] reported that tonsil volume has a negative correlation with age in patients with obstructive sleep apnea and simple snoring [32]. It may be natural that a longer period of continuously chronic inflammation should induce more atrophy of the tonsillar tissue.

Both the proportion of males and the eGFR levels are completely inconsistent in the two groups. To our knowledge, the association between the two factors and tonsil size has never been investigated, neither in IgAN nor in the healthy population. It is difficult to clarify the reasons for these results in this small study. However, we suspect that differences in age might affect the eGFR.

We evaluated histological severity using the Oxford classification [12, 13]. However, our study included patients with proteinuria of <0.5 g/day, who were excluded in the Oxford classification. Therefore, we evaluated additional lesions due to a new histological classification of IgAN, as proposed by the Special IgAN Study Group of the Progressive Glomerular Diseases Study Committee, organized by the Ministry of Health, Labour and Welfare of Japan [33]. Although some histological lesions, such as cellular crescents and tubulointerstitial changes, are considered to be influential factors for prognosis, no lesions were detected in this study. We suspect that the crescents might respond to treatment by tonsillec-toomy with SPT and that the tubulointerstitial change, the degree of which was the level of >70% of patients, was not severe enough to affect prognosis. From the viewpoint of proteinuria and renal function, the

### Table 6. Changes of serum IgA after tonsillec-toomy

|                      | At baseline | After tonsillec-toomy | P-value* |
|----------------------|-------------|-----------------------|---------|
| Hypertrophic group (n = 22)* | 302 (168) | 248 (138) [35.2 ± 28.8] | <0.001 |
| Nonhypertrophic group (n = 14)* | 318 (91) | 263 (144) [28.4 ± 18.2] | 0.012 |

Values are given as mean ± SD or median (interquartile range).

*Assessed between the two groups using the Wilcoxon signed-rank test.

*Excluding 21 patients (7 hypertrophic group, 14 nonhypertrophic group) whose serum IgA was not measured after tonsillec-toomy.
disease activities of the patients in this study look mild. Alternatively, the frequencies of some histological lesions are relatively high considering the clinically mild impression. To interpret such a sham discrepancy, we have to consider two factors: (i) a strong degree of hematuria and (ii) that almost 20% of patients did not reach proteinuria remission despite mild proteinuria. We speculate that relatively high frequencies of some histological lesions may affect these factors.

Only proteinuria was detected as a significant predictor in multivariate analysis. Proteinuria is already a factor that is well-known to influence the prognosis of IgAN [34]. This study indicates that the proteinuria had a significant impact on CR by tonsillectomy combined with SPT even in IgAN with milder proteinuria. No other covariate, such as weight of excised PTs, eGFR, systolic and diastolic BP, use of RAS inhibitor, use of antiplatelet agents and global sclerosis, had an impact. Although eGFR and global sclerosis are considered to be prognostic factors, the reason why these two covariates were not statistically significant may be that they did not range widely in value because the targeted patients in this study had only normal or mild renal dysfunction.

With respect to the limitations of this study, we must consider several issues. First, the average amount of proteinuria was mild, so the included patients are not representative of the IgAN population as a whole. In this study we included only patients who underwent a tonsillectomy before SPT to avoid the effect of steroids on histological tonsillar findings. In patients with moderate or heavy proteinuria, SPT was conducted before tonsillectomy to decrease proteinuria at an earlier time. As a result, the remaining patients who underwent tonsillectomy before SPT had relatively mild proteinuria. The second issue concerns the study population. This was a single-center study and the number of patients was small, including only patients who had undergone a tonsillectomy between January 2004 and December 2005 performed by the same two otolaryngologists, who used the same operative method to avoid technical biases by the surgery. Third, the background factors such as sex and eGFR between the two groups were not strictly equitable because of the retrospective nature of this cohort study. We performed a Cox multivariate analysis to exclude this potential bias. Fourth, treatment results did not come from tonsillectomy monotherapy but instead from tonsillectomy combined with SPT. Because even mild urinary abnormality would be a prognostic factor [21–23], we performed SPT combined with tonsillectomy for the treatment target of CR [8] at an earlier time. Because both the annual health check system and national health coverage [35] in Japan make early referral and treatment intervention possible, the treatment goal has been changing from ‘slowing the progression of nephropathy’ to ‘remission of nephropathy’.

In conclusion, although the present study is not prospective, the treatment effect of tonsillectomy combined with SPT may be equal for IgAN regardless of the size of the tonsils. In addition, nonhypertrophic tonsils have specific pathological features to PTs of IgAN that are similar to hypertrophic tonsils. Therefore, tonsil size should not be included among the factors when deciding the indication of tonsillectomy for IgAN.

Acknowledgements

We thank Mr Onodera and Mr Kitamura for skillful histological management.

Conflicts of interest statement

None declared.

References

1. D’Amico G, Ragni A, Gandini E et al. Typical and atypical natural history of IgA nephropathy in adult patients. Contrib Nephrol 1993; 104: 6–13
2. D’Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis 2000; 36: 227–237
3. Pentecost RS. Focal infection in the tonsils of adults suffering from sub-acute and chronic systemic disease: analysis of results of removal in a series of 800 cases. Can Med Assoc J 1922; 12: 886–891
4. Iino Y, Ambe K, Kato Y et al. Chronic tonsillitis and IgA nephropathy: clinical study of patients with and without tonsillectomy. Acta Otolaryngol 1993; 113(Suppl 508): 29–35
5. Kosaka M. Long-term prognosis for tonsillectomy patients with IgA nephropathy. Nihon Jibiinkoka Gakkai Kaiho 1998; 101: 916–923
6. Rasche FM, Schwarz A, Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrol 1999; 51: 147–152
7. Xie Y, Nishi S, Ueno M et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int 2003; 63: 1861–1867
8. Komatsu H, Fujimoto S, Hara S et al. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol 2008; 3: 1301–1307
9. Kawamura T, Yoshimura M, Miyazaki Y et al. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant 2014; 29: 1546–1553
10. Akagi H, Doi A, Kosaka M et al. Indication criteria for tonsillectomy in IgA nephropathy patients. Adv Otorhinolaryngol 2011; 72: 50–52
11. Tomino Y, Sakai H. Clinical guidelines for immunoglobulin A (IgA) nephropathy in Japan, second version. Clin Exp Nephrol 2003; 7: 93–97
12. Cattran DC, Coppo R, Cook HT et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76: 534–545
13. Roberts JS, Cook HT, Troyanow S et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009; 76: 546–556
14. Suzuki Y, Matsuzaki K, Suzuki H et al. Proposal of remission criteria for IgA nephropathy. Clin Exp Nephrol 2014; 18: 481–486
15. Kawaguchi M, Sakai T, Sakamaki A et al. Expanded primary T nODULES in the palatine tonsils from patients with IgA nephropathy. Acta Otolaryngol Suppl 1993; 508: 36–42
16. Takechi H, Oda T, Hotta O et al. Clinical and immunological implications of increase in CD208+ dendritic cells in tonsils of patients with immunoglobulin A nephropathy. Nephrol Dial Transplant 2013; 28: 3004–3013
17. Matutani S, Honna R, Adachi M et al. Clinical observation of palatine tonsils with IgA nephropathy. Acta Otolaryngol Suppl 2004; 555: 58–61
18. Nave H, Gebert A, Pabel R. Morphology and immunology of the human palatine tonsil. Anat Embryol (Berl) 2001; 204: 367–373
19. Hoefakker S, van ’t Erve EH, Deen C et al. Immunohistochemical detection of co-localizing cytokine and antibody producing cells in the extrafollicular area of human palatine tonsils. Clin Exp Immunol 1993; 93: 223–228
20. Tabata T, Obuchi T, Kitamura T et al. Prognostic factors of IgA nephropathy after tonsillectomy. Nihon Jibiinkoka Gakkai Kaiho 2012; 115: 836–841
21. McCullough PA, Jurkovitz CT, Pergola PE et al. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med 2007; 167: 1122–1129
22. Szeto CC, Lai FM, To KF et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med 2001; 110: 434–437
23. Shen P, He L, Li Y et al. Natural history and prognostic factors of IgA nephropathy presented with isolated microscopic hematuria in Chinese patients. Nephron Clin Pract. 2007; 106: c157–c161
24. Pozzi C, Andrulli S, Del Vecchio L et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004; 15: 157–163
25. Manno C, Strippoli GF, D’Altri C et al. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study. Am J Kidney Dis 2007; 49: 763–775
26. Béné MC, Hurnault de Ligny B, Kessler M et al. Tonsils in IgA nephropathy. Contrib Nephrol 1993; 104: 151–161
27. Akagi H, Kosaka M, Hattori K et al. Long-term results of tonsillectomy as a treatment for IgA nephropathy. Acta Otolaryngol Suppl. 2004; 555: 38–42
28. Chen Y, Tang Z, Wang Q et al. Long-term efficacy of tonsillectomy in Chinese patients with IgA nephropathy. Am J Nephrol. 2007; 27: 170–175
29. Feehally J, Coppo R, Troyanov S et al. Tonsillectomy in a European cohort of 1147 patients with IgA nephropathy. Nephron. 2016; 132: 15–24
30. Kidney Disease: Improving Global Outcome (KDIGO) clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2012; 2: 209–217
31. Hotta O. Use of corticosteroids, other immunosuppressive therapies, and tonsillectomy in the treatment of IgA nephropathy. Semin Nephrol 2004; 24: 244–255
32. Cahali MB, Soares CF, Dantas DA et al. Tonsil volume, tonsil grade and obstructive sleep apnea: is there any meaningful correlation? Clinics (Sao Paulo) 2011; 66: 1347–1351
33. Kawamura T, Joh K, Okonogi H et al. A histologic classification of IgA nephropathy for predicting long-term prognosis: emphasis on end-stage renal disease. J Nephrol 2013; 26: 350–357
34. Berthoud F, Mohey H, Laurent B et al. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 2011; 22: 752–761
35. Ikegami N, Yoo BK, Hashimoto H et al. Japanese universal health coverage: evolution, achievements, and challenges. Lancet 2011; 378: 1106–1115